Clinical trials: HIV Antibodies
HIV Infections
A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV
This study evaluates the safety, tolerability, and pharmacokinetics (PK) of a single dose administration of VH4527079 by subcutaneous (SC) injection or by intravenous (IV) infusion in healthy adult participants and multiple dose…
- Trial name
- NCT06652958
- Testing
- VH4527079
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Pulmonary Arterial Hypertension, HIV Infection
Auto-immunity and Pulmonary Arterial Hypertension
The investigators have recently evidenced the presence of antibodies to endothelial cells and fibroblasts in patients with idiopathic or SSc-associated PAH.
- Conditions
- Pulmonary Arterial Hypertension, HIV Infection, Congenital Heart Defect, Systemic Sclerosis
- Trial name
- Auto-HTAP (NCT01208792)
- Testing
- skin biopsy, Blood Sample
- Where
- 3 sites in France
- Volunteers
- 629 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV Infection
Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 704/HPTN 085 AMP Study
The purpose of this study is to learn whether having the AMP Study antibody (called VRC01) in a person's body might help their immune system control HIV better, even without HIV medication called antiretroviral therapy or ART, if…
- Trial name
- NCT04801758
- Testing
- Analytical Treatment Interruption
- Where
- 6 sites in Brazil, Peru
- Volunteers
- 18 people
- Sponsor
- HIV Vaccine Trials Network
HIV, Hepatitis C
Behavioral Science Aspects of Rapid Test Acceptance
The relevance of this research to public health is to make it possible to test for hepatitis C and syphilis at point of care so that people will receive their results immediately instead of requiring people to wait for at least a…
- Conditions
- HIV, Hepatitis C, Hepatitis B, Syphilis
- Trial name
- BSARTA (NCT01317784)
- Testing
- Rapid tests for HIV, HCV, HBV, and syphilis, HIV/HCV, HIV/syphilis
- Where
- United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- California State University, Long Beach
HIV Infections, HIV Seronegativity
A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine
The purpose of this study is to see if it is safe to give an HIV vaccine (vCP205) to volunteers who received an HIV vaccine at least 2 years ago, and to study how the immune system responds to this vaccine.
- Trial name
- NCT00001136
- Testing
- ALVAC-HIV MN120TMG (vCP205)
- Where
- 6 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Antibody Positivity, PrEP Uptake
PrEP for Prevention of HIV Transmission Among People Who Inject Drugs in Nairobi, Kenya
The investigators broadly aim at determining barriers and facilitators to PrEP uptake and adherence and retention among the study participants.
- Trial name
- NCT05465265
- Testing
- Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs)
- Where
- Kenya
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- University of Washington
HIV Infections
Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI
Participants will receive an infusion of both study drugs (3BNC117-LS and 10-1074-LS) and will discontinue antiretroviral therapy (which is the treatment for HIV) two days later.
- Trial name
- NCT05079451
- Testing
- 3BNC117-LS, 10-1074-LS
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immunodeficiency Syndrome, HIV Infection
Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist
Patients enrolled in NIH protocol 95-I-0133 at the Clinical Center may participate in an extension phase of this study in which the drug prednisone will be eliminated from the treatment regimen.
- Trial name
- NCT00001475
- Testing
- IL-2 plus Anti-TNF or Thalidomide
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
People Living With HIV, Antibody Response
RENEW-SHCS: Safety and Immunogenicity of a Recombinant HIV Env Protein Vaccine in ARV-treated Adults Living With HIV in the SHCS
A vaccine trial in which people with HIV-1 participating in the Swiss HIV Cohort Study will receive a HIV-specific vaccine to stimulate antibodies against HIV while continuing their standard antiretroviral therapy
- Trial name
- RENEW-SHCS (NCT07769983)
- Testing
- The Patients will all receive a vaccination with a recombinant HIV-1 envelope protein BG505 SOSIP.GT1.1 gp140 vaccine, adjuvanted,.
- Where
- 2 sites in Switzerland
- Volunteers
- 30 people
- Sponsor
- University of Zurich
HIV
A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies
This phase 1 study will evaluate the safety, tolerability, and immune responses of two experimental mRNA HIV vaccines in adults living with HIV who are in overall good health.
- Trial name
- NCT07569029
- Testing
- DV700P-RNA 100 mcg, DV701B1.1-RNA 100 mcg
- Where
- 16 sites in United States, Argentina and 2 more
- Volunteers
- 42 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults
The purpose of this study is to determine the safety of and immune response to an experimental HIV vaccine in HIV uninfected individuals.
- Trial name
- NCT00119873
- Testing
- VRC-HIVADV014-00-VP
- Where
- 3 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
The goal of this clinical study is to compare how effective a long-acting injectable treatment of lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) versus (CAB) and rilpivirine (RPV) injections given every 8 weeks in…
- Trial name
- NCT07682961
- Testing
- Lenacapavir, Lenacapavir Tablet, Teropavimab
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 590 people
- Sponsor
- Gilead Sciences
HIV
Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1
The investigational product, ibalizumab, is a humanized IgG4 monoclonal antibody administered via intravenous infusion at 800 mg every 2 weeks or at 2000 mg every 4 weeks.
- Trial name
- TMB-202 (NCT00784147)
- Testing
- Ibalizumab
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 113 people
- Sponsor
- TaiMed Biologics Inc.
HIV Infections
Immune Response to Influenza Vaccine in HIV-Infected Individuals
This study will evaluate how HIV infection, including CD4 cell count and viral load, affects the patient's ability to produce antibodies in response to vaccination with the influenza (flu) vaccine.
- Trial name
- NCT00069914
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Retinitis, HIV Infections
A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)
To compare the safety and efficacy of sevirumab (MSL 109; Protovir), human anti-cytomegalovirus (CMV) monoclonal antibody, plus active primary treatment versus placebo plus active primary treatment in AIDS patients with newly…
- Trial name
- NCT00000836
- Testing
- Sevirumab
- Where
- 6 sites in United States
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS
Combinatorial Therapy to Induce an HIV Remission
Combination approaches will almost certainly be required to generate durable control of HIV in the absence of antiretroviral therapy (a "remission").
- Trial name
- NCT04357821
- Testing
- Combination Intervention
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of California, San Francisco
Hepatitis C
Evaluation Study of RDTs Detecting Antibodies Against HCV
The study aims to evaluate 13 different HCV RDTs (10 on-market, 3 under development) for their diagnostic performance and operational characteristics in archived EDTA plasma samples, originating from patients from different…
- Trial name
- NCT04033887
- Testing
- 13 Rapid Diagnostic Tests and reference tests
- Where
- 3 sites in Belgium, Georgia and 1 more
- Volunteers
- 1,710 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
HIV
A Phase 1 Trial to Evaluate CAP256V2LS in Healthy Adults
Background: HIV is a serious disease with no cure or vaccine to prevent it. Using antibodies could be a way to prevent HIV infection. Antibodies are made by the human body to fight germs.
- Trial name
- VRC 611 (NCT04408963)
- Testing
- VRC-HIVMAB0102-00-AB
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant, Myeloma
Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
The primary endpoint of this study is to compare the humoral response (titre and neutralizing capacity of induced antibodies) against SARS-CoV-2 following vaccination with BNT162b2 (Pfizer BioNTech) in immunocompromised persons…
- Conditions
- Kidney Transplant, Myeloma, Cancer, Hematologic Malignancy
- Trial name
- EREVA (NCT04952766)
- Testing
- Biological samples
- Where
- France
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Régional d'Orléans
HIV Infections
The Safety and Effectiveness of Human Monoclonal Antibody, F105, in the Treatment of HIV
To determine the safety and pharmacokinetics of F105 human monoclonal antibody both following a single dose and during intermittent administration in HIV-infected patients.
- Trial name
- NCT00001105
- Testing
- F105 Monoclonal Antibody (Human)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)